Registry update — unassessed
The Use of Senolytic Agent to Improve the Benefit of Platelet-Rich Plasma and Losartan for Treatment of Femoroacetabular Impingement and Labral Tear: A Pilot Study
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 16, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract contains no outcome data, so effectiveness of fisetin as an adjunct to PRP and losartan cannot be evaluated.
- No sample size is reported, making it impossible to assess whether the pilot had adequate power or whether results would generalize.
- The mechanism by which fisetin was hypothesized to work (eliminating senescent cells in PRP) was not tested or validated in the reported material.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients suffering from femoroacetabular impingement and labral tear who are planning to undergo hip arthroscopy, recruited from The Steadman Clinic
- Primary outcome
- Improvement in beneficial effects of PRP when used with surgical treatment of femoroacetabular impingement and/or labral tear
- Effect size
- —
- Significance
- Not reported
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Sources
Primary source
- Steadman Philippon Research Institute ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The purpose is to explore the possible benefit of administration of Fisetin, (a senolytic agent) to improve the benefit of Platelet-Rich Plasma and losartan for treatment of femoroacetabular impingement and labral tear.
We believe that giving Fisetin, a senolytic agent, will improve the benefit of PRP by eliminating senescent cells and senescence-associated secretory phenotype (SASP), known to exist in PRP.
The main objectives of this study are to determine if pre- and post-operative administration of a senolytic agent will improve the beneficial effects of PRP when used in conjunction with surgical treatment of FAI and/or labral tear, to determine whether pre- and postoperative administration of Fisetin is associated with adverse events, and to determine if pre- and post-operative administration of Fisetin leads to a decrease in systemic senescence, serum SASP, and fibrotic markers.
Patients suffering from femoroacetabular impingement and labral tear, who are planning to undergo hip arthroscopy combined with standard of care intra-operative PRP injection and post-operative losartan administration will be recruited from the clinical practice of the Principal Clinical Investigator or his designee at The Steadman Clinic (TSC).
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.